BioLife Solutions BLFS Cash Cash Equivalents And Short Term Investments
Cash Cash Equivalents And Short Term Investments at other companies
Other financials
Where this comes from
Reported directly by BioLife Solutions in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.
The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioLife Solutions's cash cash equivalents and short term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioLife Solutions's cash cash equivalents and short term investments?
- BioLife Solutions (BLFS) reported cash cash equivalents and short term investments of $111.5M in Q1 2026.
- How has BioLife Solutions's cash cash equivalents and short term investments changed year-over-year?
- BioLife Solutions's cash cash equivalents and short term investments increased by 3.6% year-over-year, from $107.6M to $111.5M.
- What is the long-term trend for BioLife Solutions's cash cash equivalents and short term investments?
- Over 3 years (2022 to 2025), BioLife Solutions's cash cash equivalents and short term investments has grown at a 23.3% compound annual growth rate (CAGR), from $64.1M to $120.2M.